Compare Stocks

Date Range: 

 PhaseBio PharmaceuticalsAnebulo PharmaceuticalsMatinas BioPharmaEquilliumObsEva
SymbolNASDAQ:PHASNASDAQ:ANEBNYSEAMERICAN:MTNBNASDAQ:EQNASDAQ:OBSV
Price Information
Current Price$3.69$7.01$0.72$5.41$2.47
50-Day Moving Average$3.62$7.39$1.11$6.10$2.89
52-Week Low$2.60$6.31$0.66$3.47$1.86
52-Week High$5.83$9.33$2.22$13.50$5.55
MarketRank™
Overall Score1.61.71.21.61.2
Analysis Score3.53.53.43.53.3
Community Score2.35.02.84.62.3
Dividend Score0.00.00.00.00.0
Ownership Score1.70.00.00.00.0
Earnings & Valuation Score0.60.00.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$11.00$15.00$3.38$14.80$15.33
% Upside from Price Target198.10% upside113.98% upside369.34% upside173.57% upside520.78% upside
Trade Information
Market Cap$167.67 million$163.61 million$146.90 million$157.11 million$142.15 million
Beta1.63N/A2.571.610.76
Average Volume300,2306,007913,79596,535444,115
Sales & Book Value
Annual Revenue$320,000.00N/A$160,000.00N/A$20,000.00
Price / Sales523.98N/A918.11N/A7,107.43
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value($0.86) per shareN/A$0.30 per share$2.82 per share$0.15 per share
Price / Book-4.29N/A2.40N/A16.47
Profitability
Net Income$-98,570,000.00$170,000.00$-22,450,000.00$-29,810,000.00$-82,970,000.00
EPS($3.39)N/A($0.12)($1.46)($1.67)
Trailing P/E RatioN/A0.00N/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)-3,182.40%N/A-34.95%-45.74%-312.89%
Return on Assets (ROA)-158.49%N/A-30.09%-37.66%-98.06%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.64%N/AN/A0.08%0.51%
Current Ratio5.29%N/A28.43%14.37%4.29%
Quick Ratio5.29%N/A28.43%14.37%4.29%
Ownership Information
Institutional Ownership Percentage70.18%N/A19.34%26.28%30.68%
Insider Ownership Percentage9.00%N/A7.80%32.70%N/A
Miscellaneous
Employees502203142
Shares Outstanding45.44 million23.34 million204.28 million29.04 million57.55 million
Next Earnings Date8/10/2021 (Estimated)9/20/2021 (Estimated)8/9/2021 (Estimated)8/11/2021 (Estimated)8/5/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
ObsEva SA (NASDAQ: OBSV) Declined -17.94% Over The Last Month - Are There Ways To Succeed From This Decline? - Marketing SentinelObsEva SA (NASDAQ: OBSV) Declined -17.94% Over The Last Month - Are There Ways To Succeed From This Decline? - Marketing Sentinel
marketingsentinel.com - July 24 at 11:03 AM
Dysmenorrhea Market Projected to Show Strong Growth 2028 | AbbVie/ Neurosciences Biosciences, Nobelpharma/ASKA Pharmaceutical, ObsEva – The Manomet Current - The Manomet CurrentDysmenorrhea Market Projected to Show Strong Growth 2028 | AbbVie/ Neurosciences Biosciences, Nobelpharma/ASKA Pharmaceutical, ObsEva – The Manomet Current - The Manomet Current
manometcurrent.com - July 20 at 8:00 PM
ObsEva SA (NASDAQ:OBSV) Expected to Announce Earnings of -$0.26 Per ShareObsEva SA (NASDAQ:OBSV) Expected to Announce Earnings of -$0.26 Per Share
americanbankingnews.com - July 19 at 11:34 AM
ObsEva SA (NASDAQ: OBSV): Is This The Time To Buy? - Marketing SentinelObsEva SA (NASDAQ: OBSV): Is This The Time To Buy? - Marketing Sentinel
marketingsentinel.com - July 17 at 8:37 AM
Is the Options Market Predicting a Spike in ObsEva (OBSV) Stock? - Yahoo FinanceIs the Options Market Predicting a Spike in ObsEva (OBSV) Stock? - Yahoo Finance
finance.yahoo.com - July 12 at 2:29 PM
Is the Options Market Predicting a Spike in ObsEva (OBSV) Stock?Is the Options Market Predicting a Spike in ObsEva (OBSV) Stock?
finance.yahoo.com - July 12 at 2:29 PM
Global Menstrual Cramps Treatment Market Worldwide Opportunities, Driving Forces, Future Potential 2028||PMS4PMS, LLC, Sanofi, Nobelpharma Co., Ltd., ObsEva, Myovant Sciences Ltd., AbbVie Inc., BioElectronics Corporation – The Manomet Current - The Manomet CurrentGlobal Menstrual Cramps Treatment Market Worldwide Opportunities, Driving Forces, Future Potential 2028||PMS4PMS, LLC, Sanofi, Nobelpharma Co., Ltd., ObsEva, Myovant Sciences Ltd., AbbVie Inc., BioElectronics Corporation – The Manomet Current - The Manomet Current
manometcurrent.com - July 5 at 9:06 AM
ObsEva SA (NASDAQ:OBSV) Receives Consensus Rating of "Hold" from BrokeragesObsEva SA (NASDAQ:OBSV) Receives Consensus Rating of "Hold" from Brokerages
americanbankingnews.com - July 3 at 2:24 PM
ObsEva (NASDAQ:OBSV) Given Buy Rating at WedbushObsEva (NASDAQ:OBSV) Given Buy Rating at Wedbush
americanbankingnews.com - July 3 at 1:28 PM
Short Interest in ObsEva SA (NASDAQ:OBSV) Drops By 31.0%Short Interest in ObsEva SA (NASDAQ:OBSV) Drops By 31.0%
americanbankingnews.com - July 2 at 4:00 PM
ObsEva to Present Ebopiprant (OBE022) Data at the Society - GlobeNewswireObsEva to Present Ebopiprant (OBE022) Data at the Society - GlobeNewswire
globenewswire.com - July 2 at 1:26 PM
ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting - Yahoo FinanceObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting - Yahoo Finance
finance.yahoo.com - July 2 at 8:26 AM
ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty - GlobeNewswireObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty - GlobeNewswire
globenewswire.com - June 30 at 8:45 AM
ObsEva SA (NASDAQ:OBSV) Stock Forecast: up to 24 USD!ObsEva SA (NASDAQ:OBSV) Stock Forecast: up to 24 USD!
stocksregister.com - June 27 at 1:23 AM
ObsEva To Present Data on Two Clinical Development Programs - GlobeNewswireObsEva To Present Data on Two Clinical Development Programs - GlobeNewswire
globenewswire.com - June 24 at 9:48 AM
Do Hedge Funds Love ObsEva SA (OBSV)? - Yahoo FinanceDo Hedge Funds Love ObsEva SA (OBSV)? - Yahoo Finance
finance.yahoo.com - June 15 at 12:19 AM
Do Hedge Funds Love ObsEva SA (OBSV)?Do Hedge Funds Love ObsEva SA (OBSV)?
finance.yahoo.com - June 14 at 7:18 PM
ObsEva SA (NASDAQ:OBSV) Stock Gains Momentum After The News: Will The Rally Continue? - DRP GazetteObsEva SA (NASDAQ:OBSV) Stock Gains Momentum After The News: Will The Rally Continue? - DRP Gazette
drpgazette.com - June 10 at 10:35 PM
ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on - GlobeNewswireObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on - GlobeNewswire
globenewswire.com - June 10 at 1:10 AM
ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021
finance.yahoo.com - June 10 at 1:10 AM
Abnormal Uterine Bleeding (AUB) Market Soaring Demands by 2028 with ObsEva, Bayer, AbbVie, Myovant Sciences, AbbVie, Enteris BioPharma, Ferring Pharmaceuticals – The Manomet Current - The Manomet CurrentAbnormal Uterine Bleeding (AUB) Market Soaring Demands by 2028 with ObsEva, Bayer, AbbVie, Myovant Sciences, AbbVie, Enteris BioPharma, Ferring Pharmaceuticals – The Manomet Current - The Manomet Current
manometcurrent.com - June 8 at 6:09 PM
Ready for Takeoff? ObsEva SA (NASDAQ:OBSV) Is In News - DRP GazetteReady for Takeoff? ObsEva SA (NASDAQ:OBSV) Is In News - DRP Gazette
drpgazette.com - June 2 at 12:57 PM
ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021 - Yahoo FinanceObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021 - Yahoo Finance
finance.yahoo.com - June 2 at 7:51 AM
ObsEva SA Announces that Shareholders Approved all Board - GlobeNewswireObsEva SA Announces that Shareholders Approved all Board - GlobeNewswire
globenewswire.com - May 31 at 9:59 AM
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021
benzinga.com - May 31 at 1:16 AM
DateCompanyBrokerageAction
7/14/2021EquilliumHC Wainwright
Reiterated Rating
7/2/2021ObsEvaWedbush
Reiterated Rating
6/17/2021PhaseBio PharmaceuticalsNeedham & Company LLC
Lower Price Target
6/15/2021EquilliumSVB Leerink
Reiterated Rating
5/25/2021Anebulo PharmaceuticalsBenchmark
Initiated Coverage
5/18/2021EquilliumSVB Leerink
Reiterated Rating
5/11/2021Matinas BioPharmaPiper Sandler
Downgrade
4/1/2021EquilliumSVB Leerink
Reiterated Rating
3/30/2021Matinas BioPharmaHC Wainwright
Reiterated Rating
3/18/2021PhaseBio PharmaceuticalsStifel Nicolaus
Reiterated Rating
3/16/2021PhaseBio PharmaceuticalsNeedham & Company LLC
Boost Price Target
3/3/2021EquilliumJonestrading
Initiated Coverage
2/15/2021Matinas BioPharmaAegis
Reiterated Rating
2/9/2021EquilliumHC Wainwright
Reiterated Rating
1/29/2021Matinas BioPharmaMaxim Group
Reiterated Rating
1/12/2021ObsEvaWedbush
Reiterated Rating
1/12/2021ObsEvaSVB Leerink
Boost Price Target
1/4/2021Matinas BioPharmaPiper Sandler
Boost Price Target
1/4/2021ObsEvaHC Wainwright
Lower Price Target
11/30/2020EquilliumHC Wainwright
Lower Price Target
11/30/2020EquilliumHC Wainwright
Reiterated Rating
11/9/2020ObsEvaJPMorgan Chase & Co.
Downgrade
11/6/2020Matinas BioPharmaMaxim Group
Initiated Coverage
10/5/2020ObsEvaHC Wainwright
Lower Price Target
9/21/2020EquilliumHC Wainwright
Reiterated Rating
8/25/2020PhaseBio PharmaceuticalsCitigroup
Lower Price Target
8/21/2020EquilliumHC Wainwright
Lower Price Target
8/14/2020ObsEvaWedbush
Reiterated Rating
8/13/2020Matinas BioPharmaAegis
Boost Price Target
8/13/2020EquilliumJefferies Financial Group
Reiterated Rating
8/11/2020PhaseBio PharmaceuticalsStifel Nicolaus
Reiterated Rating
8/11/2020Matinas BioPharmaHC Wainwright
Reiterated Rating
8/10/2020EquilliumStifel Nicolaus
Reiterated Rating
7/13/2020EquilliumHC Wainwright
Reiterated Rating
7/13/2020EquilliumStifel Nicolaus
Reiterated Rating
7/7/2020ObsEvaSVB Leerink
Lower Price Target
7/7/2020ObsEvaJPMorgan Chase & Co.
Downgrade
7/6/2020ObsEvaBMO Capital Markets
Downgrade
7/1/2020ObsEvaHC Wainwright
Reiterated Rating
7/1/2020ObsEvaWedbush
Reiterated Rating
6/5/2020ObsEvaHC Wainwright
Reiterated Rating
6/2/2020Matinas BioPharmaAegis
Reiterated Rating
5/29/2020PhaseBio PharmaceuticalsCitigroup
Boost Price Target
5/28/2020PhaseBio PharmaceuticalsNeedham & Company LLC
Initiated Coverage
5/26/2020EquilliumHC Wainwright
Reiterated Rating
5/23/2020Matinas BioPharmaMaxim Group
Initiated Coverage
5/19/2020EquilliumHC Wainwright
Reiterated Rating
5/13/2020Matinas BioPharmaMaxim Group
Reiterated Rating
5/5/2020PhaseBio PharmaceuticalsStifel Nicolaus
Reiterated Rating
5/5/2020ObsEvaWedbush
Reiterated Rating
4/6/2020PhaseBio PharmaceuticalsCitigroup
Lower Price Target
4/1/2020Matinas BioPharmaMaxim Group
Initiated Coverage
3/27/2020EquilliumHC Wainwright
Reiterated Rating
3/23/2020ObsEvaWedbush
Reiterated Rating
3/23/2020ObsEvaHC Wainwright
Lower Price Target
3/6/2020Matinas BioPharmaMaxim Group
Reiterated Rating
3/5/2020ObsEvaWedbush
Boost Price Target
1/26/2020Matinas BioPharmaPiper Sandler
Initiated Coverage
1/23/2020Matinas BioPharmaSunTrust Banks
Initiated Coverage
1/21/2020ObsEvaWedbush
Reiterated Rating
1/21/2020ObsEvaHC Wainwright
Reiterated Rating
1/9/2020Matinas BioPharmaAegis
Initiated Coverage
1/2/2020EquilliumSVB Leerink
Reiterated Rating
12/30/2019EquilliumHC Wainwright
Reiterated Rating
12/20/2019PhaseBio PharmaceuticalsHC Wainwright
Reiterated Rating
12/20/2019Matinas BioPharmaHC Wainwright
Reiterated Rating
12/19/2019ObsEvaHC Wainwright
Reiterated Rating
12/10/2019ObsEvaRoyal Bank of Canada
Boost Price Target
12/2/2019ObsEvaHC Wainwright
Reiterated Rating
11/8/2019ObsEvaCredit Suisse Group
Downgrade
10/31/2019ObsEvaWedbush
Reiterated Rating
10/11/2019ObsEvaWedbush
Set Price Target
10/3/2019PhaseBio PharmaceuticalsHC Wainwright
Initiated Coverage
9/26/2019Matinas BioPharmaMaxim Group
Reiterated Rating
9/24/2019PhaseBio PharmaceuticalsCowen
Reiterated Rating
9/11/2019PhaseBio PharmaceuticalsWilliam Blair
Reiterated Rating
9/9/2019PhaseBio PharmaceuticalsStifel Nicolaus
Lower Price Target
8/14/2019Matinas BioPharmaHC Wainwright
Reiterated Rating
8/13/2019EquilliumHC Wainwright
Reiterated Rating
7/12/2019EquilliumHC Wainwright
Initiated Coverage
7/2/2019EquilliumHC Wainwright
Initiated Coverage
6/26/2019Matinas BioPharmaHC Wainwright
Reiterated Rating
6/26/2019Matinas BioPharmaHC Wainwright
Initiated Coverage
5/24/2019PhaseBio PharmaceuticalsCitigroup
Set Price Target
5/17/2019Matinas BioPharmaBTIG Research
Initiated Coverage
5/16/2019Matinas BioPharmaMaxim Group
Reiterated Rating
2/22/2019EquilliumSVB Leerink
Reiterated Rating
2/11/2019Matinas BioPharmaRoth Capital
Reiterated Rating
2/11/2019Matinas BioPharmaRoth Capital
Initiated Coverage
11/13/2018PhaseBio PharmaceuticalsNeedham & Company LLC
Initiated Coverage
11/12/2018PhaseBio PharmaceuticalsCowen
Initiated Coverage
11/12/2018PhaseBio PharmaceuticalsCitigroup
Initiated Coverage
11/12/2018PhaseBio PharmaceuticalsStifel Nicolaus
Initiated Coverage
11/6/2018EquilliumJefferies Financial Group
Initiated Coverage
11/6/2018EquilliumStifel Nicolaus
Initiated Coverage
(Data available from 7/25/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.